Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

About this update from Co-diagnostics, Inc.

[{"type":"image","alt":"Co-Diagnostics, Inc.","displaySize":"","headline":null,"caption":"Co-Diagnostics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/0ebc7050ab07aee577f32c88ed97ea16"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KPIyIM2Wq1XQW5Frq7OjjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0ebc7050ab07aee577f32c88ed97ea16","width":300,"height":138}},"lazy":false},{"type":"text","content":"SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025.","length":273,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Results:","length":37,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"●","length":1,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025","length":208,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"●","length":1,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter"...

More updates from Co-diagnostics, Inc.